Albert Bourla - Pfizer Insider

PFE -- Germany Stock  

EUR 37.46  0.01  0.0267%

Mr. Albert Bourla is the Chief Operating Officer, Director of Pfizer Inc. He was Group President, Global Innovative Pharma Business from February 2016 until June 2016 and Group President, Vaccines, Oncology and Consumer Healthcare since January 2014. President and General Manager of Established Products Business Unit from December 2010 until December 2013. Area President Europe, Africa, Asia and Pacific of Pfizer Animal Health from 2009 until November 2010. Area President Europe, Africa and Middle East of Pfizer Animal Health from 2005 until 2009. Board member of the Pfizer Foundation, which promotes access to quality healthcare. Board member and serves on the Executive Committee of the Biotechnology Innovation Organization, the worlds largest biotechnology trade association. Dr. Bourla has over 25 years of leadership experience and a demonstrated track record for delivering strong business results. Dr. Bourla has deep knowledge of the healthcare industry as he has held a number of senior global positions across a range of businesses and geographies over the course of his career, which enables him to provide important insights and perspectives to our Board on the companys commercial, strategic, manufacturing and global product development functions. In addition, his experiences on the Executive Committee of the Biotechnology Innovation Organization provides him with a broader perspective on issues facing our industry. Dr. Bourla brings expertise in medicine and science to the Board through his prior experiences working within Pfizers Animal Health business and as a veterinarian.
Age: 55  President Since 2018  Ph.D    

Albert Bourla Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 5.73 % which means that it generated profit of $5.73 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 35.08 % meaning that it generated $35.08 on every $100 dollars invested by stockholders.
The company has accumulated 41.03 B in total debt with debt to equity ratio (D/E) of 58.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Pfizer has Current Ratio of 1.14 suggesting that it may have difficulties to pay its financial obligations in time and when they become due.

Similar Executives

Showing few of many executives


Jim McCarthyRockwell Medical
Jonathan ColmanSekisui Chemical Co Ltd
Karen DearingSekisui Chemical Co Ltd
Maria CroweEli Lilly and Company
Michael HarringtonEli Lilly and Company
Enrique ConternoEli Lilly and Company
Joseph WolkJohnson Johnson
Jan LundbergEli Lilly and Company
Susan MahonyEli Lilly and Company
Stephen FryEli Lilly and Company
Melissa BarnesEli Lilly and Company
Kathy WengelJohnson Johnson
Michael SneedJohnson Johnson
Joshua SmileyEli Lilly and Company
Louise MehrotraJohnson Johnson
Jeffrey SimmonsEli Lilly and Company
John McLarenSekisui Chemical Co Ltd
Darren CarrollEli Lilly and Company
Derica RiceEli Lilly and Company
Peter FasoloJohnson Johnson
David RicksEli Lilly and Company

Entity Summary

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug Manufacturers - Major classification in Germany and traded on Frankfurt Stock Exchange. It employs 90200 people.Pfizer (PFE) is traded on Frankfurt Stock Exchange in Germany. It is located in 235 East 42nd Street and employs 90,200 people.

Pfizer Leadership Team

John Young, Group President - Global Established Pharma Business
Frank DAmelio, CFO, Executive Vice President - Business Operations
Douglas Lankler, Executive Vice President General Counsel
Helen Hobbs, Independent Director
Shantanu Narayen, Director
James Smith, Director
Dennis Ausiello, Independent Director
Mikael Dolsten, President - Worldwide Research and Development
Frances Fergusson, Independent Director
Stephen Sanger, Independent Director
Wyllie Cornwell, Independent Director
Suzanne Johnson, Independent Director
Alexander Mackenzie, Executive Vice President Chief Development Officer
Geno Germano, Group President - Global Innovative Pharma Business
Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial Operations
Sally Susman, Executive Vice President - Corporate Affairs
Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global Supply
Freda LewisHall, Executive Vice President Chief Medical Officer
Rady Johnson, Executive Vice President Chief Compliance and Risk Officer
Dan Littman, Director
Ian Read, Chairman of the Board, CEO
James Kilts, Independent Director
Don Cornwell, Independent Director
Charles Hill, Executive Vice President - Worldwide Human Resources
Joseph Echevarria, Director
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business
Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global Supply
Angela Hwang, Group President - Pfizer Essential Health
Ronald Blaylock, Independent Director
Kathrin Jansen, Senior Vice President - Vaccine Research & Development

Stock Performance Indicators

Did you try this?

Run Focused Opportunities Now


Focused Opportunities

Build portfolios using our predefined set of ideas and optimize them against your investing preferences
All  Next Launch Focused Opportunities
Currently Active Assets on Macroaxis
Purchased a lot of shares of
few days ago
Traded for 156.0
Purchased a lot of shares of
few days ago
Traded for 156.0
Purchased over 300 shares of
few days ago
Traded for 9.81
Purchased over 40 shares of
few days ago
Traded for 74.735
Purchased over 70 shares of
few days ago
Traded for 36.08
Additionally take a look at Your Equity Center. Please also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.